amorchem header logo close button Menu
arrow leftBack to portfolio


This program centers on the validation and proof of concept of single domain antibodies (sdAb) targeting PCSK9. This target remains very attractive to the pharmaceutical industry, with the recent approval of anti-PCSK9 biologics validating the clinical and commercial potential of this target. In collaboration with the National Research Council of Canada (NRC), Dr. Seidah (Institut de recherche Clinique de Montréal (IRCM)) screened a library of single domain antibodies against PCSK9 and identified 10 sdAb hits. These hits were validated in both cell-based assays and animal models.